Balanced news tone
News Sentiment
ARVN sentiment intelligence
Arvinas Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-1.4% over one week, +9.1% over four weeks, trend inactive, and below fair value.
Arvinas (ARVN) Proxy filing Summary
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Arvinas (ARVN) Proxy filing Summary
Arvinas (ARVN) released a summary of its proxy filing, detailing the upcoming annual meeting on June 24, 2026. Shareholders will vote on director elections, executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor. The board recommends voti
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jul 2026 09:41
- Source
- Quartr
Trading the Move, Not the Narrative: (ARVN) Edition
This article analyzes Arvinas Inc. (NASDAQ: ARVN) using AI models to provide trading strategies based on different risk profiles and holding periods. It highlights weak near-term sentiment but long-term strength, with specific entry, target, and stop-loss levels for position trad
- Tone
- Negative 40/100
- Event
- Analyst action
- Published
- 17 Jul 2026 05:34
- Source
- Stock Traders Daily
Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jul 2026 18:49
- Source
- Market source
Arvinas (ARVN) Stock Forum and Discussion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:32
- Source
- Moomoo
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
ARVN News | ARVINAS INC (NASDAQ:ARVN)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 21:48
- Source
- ChartMill
Morgan Stanley (ARVN) broker files Form 144 to sell 24,000 shares
Morgan Stanley Smith Barney LLC has filed a Form 144 notice indicating its intent to sell 24,000 shares of common stock in Arvinas, Inc. (ARVN). These sales are tied to restricted stock vesting under a registered plan, with specific vesting lots scheduled for March 2025, February
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 20:41
- Source
- Stock Titan
ARVN - Arvinas Inc Latest SEC Filings
This article provides a detailed financial overview and recent SEC filing information for Arvinas Inc. (ARVN). It covers various financial metrics including market capitalization, sales, income, profitability ratios, insider and institutional ownership, stock performance, and ana
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 10:10
- Source
- Finviz
Arvinas (ARVN) director receives RSU and stock option grants in equity award
Arvinas (ARVN) director Leslie V. Norwalk received routine equity compensation through a grant of 15,527 restricted stock units (RSUs) and an option to purchase 22,714 shares of common stock at $8.05 per share. These awards, granted on June 24, 2026, are not open-market trades an
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 08:10
- Source
- Stock Titan
Form 4 Arvinas Inc For: 26 June By Investing.com
This article from Investing.com reports the filing of a Form 4 for Arvinas Inc. on June 26. The content includes market data for various indices, currencies, and commodities, reflecting market performance. It also lists trending stocks and popular articles related to financial ne
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 22:26
- Source
- Investing.com South Africa
Arvinas (ARVN) director Briggs Morrison granted RSUs and stock options
Arvinas (ARVN) director Briggs Morrison was granted 15,527 restricted stock units (RSUs) and 22,714 stock options with an exercise price of $8.05 per share. These equity awards, reported on a Form 4 filing, are subject to vesting criteria tied to continued service and the company
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:41
- Source
- Stock Titan
Director Linda Bain receives RSUs and stock options at Arvinas (ARVN)
Arvinas, Inc. director Linda Bain was granted 15,527 restricted stock units (RSUs) and stock options for 22,714 shares at an exercise price of $8.05 per share. Both the RSUs and options vest fully on the earlier of June 24, 2027, or immediately before the first annual stockholder
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:41
- Source
- Stock Titan
[Form 4] ARVINAS, INC. Insider Trading Activity
Edward M. Kennedy Jr., a director at ARVINAS, INC. (ARVN), received new equity awards comprising 15,527 restricted stock units (RSUs) and an option to purchase 22,714 shares at an exercise price of $8.05 per share. These awards were granted on June 24, 2026, and are set to vest f
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:41
- Source
- Stock Titan
Arvinas (ARVN) director receives new RSU and stock option awards
Arvinas, Inc. director Everett Cunningham was granted 15,527 restricted stock units (RSUs) and a stock option for 22,714 shares at an exercise price of $8.05, according to a June 24, 2026 filing. Both awards are set to vest on the earlier of June 24, 2027, or immediately before t
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:37
- Source
- Stock Titan
Arvinas (NASDAQ: ARVN) director receives RSU and option grants in new Form 4
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Stock Titan
Arvinas, Inc. Actuals & Estimates (NASDAQ:ARVN)
This article provides key financial actuals and estimates for Arvinas, Inc. (NASDAQ:ARVN), including its current stock price, market capitalization, historical highs and lows, and analyst forecasts. It also details recent earnings, revenue, net income, and upcoming earnings repor
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 06:41
- Source
- TradingView
Arvinas Inc (ARVN) Institutional Confidence
Arvinas Inc (ARVN) has an institutional shareholding score of 7.00, placing it 80th out of 387 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 83.59%, which is a decrease of 50.35% quarter-over-quarter. Bill Nygren | OAKMX is the lar
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 26 Jun 2026 04:40
- Source
- TradingKey
Arvinas (NASDAQ: ARVN) investors back directors, pay and auditor
Arvinas, Inc. held its annual meeting on June 24, 2026, where stockholders elected Leslie V. Norwalk, Esq. and Randy Teel, Ph.D. as Class II directors. They also approved, on a non-binding advisory basis, the compensation for named executive officers and ratified Deloitte & Touch
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 20:40
- Source
- Stock Titan
Arvinas CFO Andrew Saik sells $46,473 in company stock
Arvinas CFO Andrew Saik sold 5,696 shares of company stock for $46,473 to cover tax withholding obligations related to the vesting of restricted stock units. This was not a discretionary trade. The stock is currently trading below its fair value, despite a recent earnings report
- Tone
- Negative 41/100
- Event
- Earnings
- Published
- 25 Jun 2026 20:09
- Source
- Investing.com
Form 4 Arvinas Inc For: 24 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Arvinas Inc (ARVN) dated June 24, 2026. Form 4s disclose transactions by company insiders, but the article provides no specific details about the transactions, only listing the filing and referencing the stock ticker.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 19:37
- Source
- Investing.com Nigeria
ARVN Forecast — Price Target — Prediction for 2027
This article provides a forecast for Arvinas, Inc. (ARVN) stock, including analyst price targets, current stock performance, and financial data. It highlights that the stock has a price target of 15.07 USD based on 14 analysts, with a max estimate of 24.00 USD and a min of 6.00 U
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Jun 2026 18:40
- Source
- TradingView
ARVINAS (ARVN) CFO auto-sells shares to cover RSU tax withholding
ARVINAS, INC.'s Chief Financial Officer, Andrew Saik, automatically sold 5,696 shares of common stock at $8.159 per share to cover tax withholding obligations related to the vesting of his restricted stock units. This was a non-discretionary sale made by the company and not a per
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 21:10
- Source
- Stock Titan
Form 144 Arvinas Inc For: 23 June By Investing.com
This article from Investing.com reports on Form 144 for Arvinas Inc. filed on June 23rd. Form 144 is a notice of the intent to sell restricted securities. The brief article provides no further details beyond the filing date and company name.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 18:11
- Source
- Investing.com Nigeria
ARVN: All voting items passed at the virtual meeting, with no shareholder questions submitted
Arvinas, Inc. (ARVN) held its virtual Annual General Meeting (AGM) where all proposed agenda items were approved by shareholders. These items included director elections, executive compensation, and auditor ratification. No shareholder questions were submitted during the meeting.
- Tone
- Positive 61/100
- Event
- Market update
- Published
- 24 Jun 2026 13:41
- Source
- TradingView
Arvinas (NASDAQ: ARVN) to settle 5,846 vested RSU shares on 06/24/2026
Arvinas, Inc. (NASDAQ: ARVN) is set to settle 5,846 shares of common stock stemming from vested restricted stock units on June 24, 2026, through Morgan Stanley Smith Barney LLC. The SEC Form 144 filing also notes a previous disposition of 11,139 shares by Andrew Saik on May 11, 2
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 21:40
- Source
- Stock Titan
[8-K] ARVINAS, INC. Reports Material Event
ARVINAS, INC. has reported a material event in an 8-K filing, announcing that Chief Medical Officer Noah Berkowitz, M.D., Ph.D. will depart from the company on July 3, 2026. A separation agreement includes nine months of base salary, health premiums, and accelerated vesting of ce
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 05:40
- Source
- Stock Titan
Arvinas, Inc. $ARVN Stock Holdings Lifted by Armistice Capital LLC
Armistice Capital LLC significantly increased its stake in Arvinas, Inc. (NASDAQ:ARVN) by 50% in the fourth quarter, now holding 1.8 million shares valued at $21.35 million. While institutional investors are increasing positions, company insiders, including the CFO, recently sold
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 19 Jun 2026 22:09
- Source
- MarketBeat
Arvinas (ARVN) CSO has shares sold automatically to cover RSU tax withholding
Arvinas, Inc.'s Chief Scientific Officer, Angela M. Cacace, automatically sold 2,576 shares of common stock at $7.595 per share. This non-discretionary sale was executed by the issuer to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs).
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 19:43
- Source
- Stock Titan
Rigel Deal for VEPPANU Cleared, Arvinas Receives Payment
Rigel Pharmaceuticals has secured exclusive global rights to develop and commercialize VEPPANU from Arvinas and Pfizer, following the early termination of the Hart-Scott-Rodino waiting period. This agreement triggered an upfront payment of $70 million, shared by Arvinas and Pfize
- Tone
- Positive 64/100
- Event
- Deals and strategy
- Published
- 18 Jun 2026 05:40
- Source
- The Globe and Mail
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates
Arvinas Inc (ARVN) has an earnings forecast score of 7.40, ranking 293 out of 388 in the Biotechnology & Medical Research industry. The average analyst price target for ARVN is $14.00, with 18 analysts predominantly recommending a "Buy" trend. The company's expected revenue for t
- Tone
- Positive 76/100
- Event
- Earnings
- Published
- 17 Jun 2026 23:09
- Source
- TradingKey